iBio, Inc. (IBIO) · Nov 20, 2026 · Delisting
Bid-price deficiency — Below $1.00 for 30 consecutive business days; cure deadline May 18, 2027
iBio’s delisting notice flags a sub-$1 bid price, giving the clinical-stage biotech 180 days to regain Nasdaq compliance or pursue a reverse split.
iBio is a clinical-stage AI biotech transitioning from discovery into human testing, with IBIO-600 in a Phase 1 trial and additional obesity and cardiometabolic programs still preclinical. The filing adds a real corporate constraint, not an operating milestone: Nasdaq says iBio failed to maintain the required $1.00 closing bid price for 30 consecutive business days, while the shares remain listed and trading for now.
The immediate consequence is time, not delisting: iBio has until May 18, 2027 to close at or above $1.00 for at least 10 consecutive business days. If it cannot, it may seek a second 180-day period, but that depends on meeting other Nasdaq standards and could require a reverse stock split. 〔0〕
This weakens the current story modestly because it introduces financing and capital-structure friction: maintaining a Nasdaq listing may require a reverse split, which would change the share count and price mechanics without improving the underlying drug pipeline. The filing does not signal a clinical setback or cash crisis; it signals that the market’s current valuation has created a listing problem the company must solve while advancing its programs. 〔1〕
Bottom line: This does not overturn iBio’s drug-development story, but it adds a meaningful execution risk: the company must restore its bid price or potentially restructure its share count to remain on Nasdaq.
Bid-price compliance or reverse-split decision by May 18, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!